# SAFETY DATA SHEET



## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

PROMACTA TABLETS

Registration number

**Synonyms** ELTROMBOPAG TABLETS 200MG AND 300MG \* REVOLADE TABLETS \* SB-497115-GR

> TABLETS \* PROMACTA 5 MG TABLETS \* PROMACTA 10 MG TABLETS \* PROMACTA 12.5 MG TABLETS \* PROMACTA 25 MG TABLETS \* PROMACTA 50 MG TABLETS \* PROMACTA 75 MG TABLETS \* PROMACTA 100 MG TABLETS \* PROMACTA 200 MG TABLETS \* PROMACTA 300

MG TABLETS \* ELTROMBOPAG OLAMINE, FORMULATED PRODUCT

Issue date 29-November-2013

Version number

**Revision date** 29-November-2013 Supersedes date 25-November-2013

## 1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

#### 1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

#### **SECTION 2: Hazards identification**

#### 2.1. Classification of the substance or mixture

## Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

#### Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

## 2.2. Label elements

#### Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

#### SECTION 3: Composition/information on ingredients

## 3.2. Mixtures

Material name: PROMACTA TABLETS SDS UK **General information** 

CAS-No. / EC No. REACH Registration No. INDEX No. Chemical name **Notes** 

**ELTROMBOPAG OLAMINE** 5.0 - 40.0 496775-62-3

Classification: **DSD:** Xn;R22, Xi;R41, N;R51-53

CLP: Acute Tox. 4;H302, Eye Dam. 1;H318, STOT RE 2;H373, Aquatic Chronic 2;H411

Polyvinylpyrrolidone <4.0 9003-39-8

Classification: **DSD:** R52/53

CLP: Aquatic Chronic 3;H412

MAGNESIUM STEARATE <3.0 557-04-0

209-150-3

Classification: **DSD:** Xi;R36/37/38

Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335

Titanium dioxide <3.0 13463-67-7

236-675-5

Classification: DSD: -

CLP: -

50.0 - 85.0 Other components below reportable levels

CLP: Regulation No. 1272/2008. DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

The full text for all R- and H-phrases is displayed in section 16. Composition comments

# **SECTION 4: First aid measures**

**General information** Pre-placement and periodic health surveillance is not usually indicated. The final determination of

the need for health surveillance should be determined by local risk assessment. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect

themselves.

4.1. Description of first aid measures

Inhalation In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is

difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get

medical attention if symptoms occur.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Immediately flush eyes with plenty of water for at least 15 minutes. Get medical attention if

irritation develops and persists.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately.

4.2. Most important symptoms and effects, both acute and

delayed

Irritation of eyes and mucous membranes.

The following adverse effects have been noted with therapeutic use of this material: nausea; diarrhoea; vomiting; changes in clinical chemistry parameters; muscle pain; abnormal nervous

system sensations; rash.

4.3. Indication of any immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

**SECTION 5: Firefighting measures** 

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

media

Unsuitable extinguishing None known.

media

Material name: PROMACTA TABLETS

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

In the event of fire, cool tanks with water spray.

#### **SECTION 6: Accidental release measures**

#### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

MSDS.

6.2. Environmental precautions

Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Collect spillage. Prevent product from entering

drains. Following product recovery, flush area with water.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13.

## **SECTION 7: Handling and storage**

7.1. Precautions for safe handling

Do not get this material in contact with eyes. Do not taste or swallow. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash hands thoroughly after handling. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store

away from incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s) Medicinal Product

## **SECTION 8: Exposure controls/personal protection**

# 8.1. Control parameters

## Occupational exposure limits

GS	K
----	---

Components	Туре	Value	
ELTROMBOPAG OLAMINE (CAS 496775-62-3)	8 HR TWA	100 mcg/m3	
,	OHC	3	
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
UK. EH40 Workplace Exposure Lir	nits (WELs)		
Components	` Type	Value	Form
Titanium dioxide (CAS	TWA	4 mg/m3	Respirable.

Recommended monitoring procedures

13463-67-7)

Follow standard monitoring procedures.

Derived No Effect Level (DNEL)

Not available. Not available.

Predicted no effect concentrations (PNECs)

8.2. Exposure controls

Appropriate engineering

controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

10 mg/m3

Inhalable

128838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013

## Individual protection measures, such as personal protective equipment

**General information** Eye wash fountain is recommended. Personal protection equipment should be chosen according

> to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection Eye wash fountain is recommended. If contact is likely, safety glasses with side shields are

recommended. (eg. EN 166)

Skin protection

- Hand protection The choice of an appropriate glove does not only depend on its material but also on other quality

features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN

374) with a protective index 6 (>480min permeation time).

- Other Not normally needed.

Respiratory protection No personal respiratory protective equipment normally required. Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An occupational/industrial hygiene monitoring method has been developed for this material. For

advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. When using, do not eat, drink or smoke. Keep away from food and drink. Wash contaminated clothing before reuse. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking.

Routinely wash work clothing and protective equipment to remove contaminants.

#### **Environmental exposure controls**

Hazard guidance and control recommendations

Contain spills and prevent releases and observe national regulations on emissions. Environmental manager must be informed of all major releases.

## **SECTION 9: Physical and chemical properties**

#### 9.1. Information on basic physical and chemical properties

**Appearance** 

Physical state Solid. **Form** Tablet.

Colour Not available. Odour Not available. **Odour threshold** Not available. pН Not available. Not available. Melting point/freezing point

Initial boiling point and boiling

range

Not available.

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Not available. Vapour pressure Not available. Vapour density Not available. Relative density Solubility(ies) Not available. Partition coefficient

Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature** 

**Decomposition temperature** Not available. Viscosity Not available. **Explosive properties** Not available. Oxidizing properties Not available.

9.2. Other information No relevant additional information available.

# **SECTION 10: Stability and reactivity**

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials. 10.5. Incompatible materials Strong oxidising agents. Fluorine.

10.6. Hazardous Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

decomposition products

## **SECTION 11: Toxicological information**

**General information** Occupational exposure to the substance or mixture may cause adverse effects.

#### Information on likely routes of exposure

Health injuries are not known or expected under normal use. May be harmful if swallowed. Ingestion Inhalation Health injuries are not known or expected under normal use. Inhalation of dusts may cause

respiratory irritation.

Skin contact Health injuries are not known or expected under normal use. Dust or powder may irritate the skin. Eye contact

Health injuries are not known or expected under normal use. Dust or powder may irritate eye

tissue.

**Symptoms** Irritation of eyes and mucous membranes.

The following adverse effects have been noted with therapeutic use of this material: nausea; diarrhoea; vomiting; changes in clinical chemistry parameters; muscle pain; abnormal nervous

> 24 g/kg

system sensations; rash.

## 11.1. Information on toxicological effects

LD50

Health injuries are not known or expected under normal use. Adverse effects might occur with **Acute toxicity** 

repeated ingestion.

Components	Species	Test results
ELTROMBOPAG OLAMINE (C	CAS 496775-62-3)	
Acute		
Oral		
Evident toxicity	Dog	100 mg/kg
MLD	Dog	> 300 mg/kg
Subacute		
Oral		
MTD	Rat	500 mg/kg, 2 days, Micronucleus test
Subchronic		
Oral		
NOAEL	Rat	30 mg/kg/day, 28 day study
MAGNESIUM STEARATE (CA	S 557-04-0)	
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
Polyvinylpyrrolidone (CAS 900)	3-39-8)	
Acute		
Oral		
LD50	Rat	> 5000 mg/kg
Titanium dioxide (CAS 13463-6	67-7)	
Acute		
Inhalation		
LC50	Rat	6820 mcg/m3
Oral		

128838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013

Rat

Components	Species	Test results
Chronic		
Inhalation		
LOEC	Rat	8.6 mg/m3, 1 years, TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years, Highest dose
		5 mg/m3, 24 months
Subacute		
Inhalation		
LOEL	Rat	0.1 - 35 mg/m3, 4 weeks, Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks, No evidence of significant inflammation in respiratory tract.
Oral		
NOAEL	Rat	100000 ppm, 14 Day, Dietary study, highest dose tested.
Subchronic		
Inhalation		
LOEC	Rat	3.2 - 20 mg/m3, 8 min, Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

**Irritation Corrosion - Skin** 

TITANIUM DIOXIDE Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit Literature data Result: Non-irritant Species: Guinea pig Literature data Result: Non-irritant Species: Human

**ELTROMBOPAG OLAMINE** Reconstituted Human Epidermis (RHE)

Result: negative

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE 0

Serious eye damage/eye irritation

Health injuries are not known or expected under normal use. Dust or powder may irritate eye

tissue.

Eve

**ELTROMBOPAG OLAMINE IRE Assay** 

> Result: Severe Irritant Species: Rabbit

TITANIUM DIOXIDE OECD 405, Literature data

Result: Mild irritant Species: Rabbit

**ELTROMBOPAG OLAMINE** Reconstituted Human Corneal Epithelium (HCE)

Result: Inconclusive

**Respiratory sensitisation** Not available.

Skin sensitisation Health injuries are not known or expected under normal use.

**Sensitisation** 

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: negative Species: Guinea pig

Test Duration: 48 hour exposure

**ELTROMBOPAG OLAMINE** OECD 429 / Local Lymph Node Assay, Maximum

concentration = 50%; vehicle = acetone:olive oil 4:1

Result: negative Species: Mouse

Material name: PROMACTA TABLETS

SDS UK 6 / 12 128838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013

Sensitisation

ELTROMBOPAG OLAMINE Occupational exposure

Result: Plausible Species: Human

TITANIUM DIOXIDE Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Germ cell mutagenicity

Mutagenicity

ELTROMBOPAG OLAMINE Ames Assay, GLP assay

TITANIUM DIOXIDE Result: negative Ames, Literature data

Result: negative

ELTROMBOPAG OLAMINE In Vitro Chromosomal Aberration with ultraviolet light, CHO

cells

Result: positive

TITANIUM DIOXIDE Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

ELTROMBOPAG OLAMINE Micronucleus Assay, GLP assay; tested to MTD of 500

mg/kg (oral) Result: negative Species: Rat

Mouse Lymphoma Cell (L5178Y) Mutation Test, GLP assay

Result: positive

TITANIUM DIOXIDE Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

ELTROMBOPAG OLAMINE Unscheduled DNA Synthesis, in vivo - in vitro, tested to MTD

of 500 mg/kg (oral) Result: negative Species: Rat

TITANIUM DIOXIDE WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Carcinogenicity

Health injuries are not known or expected under normal use. This product is not considered to be

a carcinogen by IARC, ACGIH, NTP, or OSHA.

TITANIUM DIOXIDE 0.5 mg/m3, Literature data

Result: negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

ELTROMBOPAG OLAMINE 2 year bioassay

Result: negative Species: Rat 2 year bioassay Species: Mouse

TITANIUM DIOXIDE 25000 - 50000 ppm, Dietary study

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

IARC Monographs. Overall Evaluation of Carcinogenicity

Polyvinylpyrrolidone (CAS 9003-39-8) 3 Not classifiable as to carcinogenicity to humans.

Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

**Reproductive toxicity** This product is not expected to cause reproductive or developmental effects.

#### Reproductive toxicity

#### Reproductivity

**ELTROMBOPAG OLAMINE** Embryo-foetal development - Oral

Result: NOAEL = 150 mg/kg/day (maximum dose); no

evidence of adverse foetal effects

Species: Rabbit

Embryo-foetal development - Oral

Result: NOAEL = 20 mg/kg/day; LOAEL = 60 mg/kg/day /

maternal toxicity, decreased foetal body weight

Species: Rat

Female Fertility / Early Embryonic Development

Result: NOAEL = 20 mg/kg/day; LOAEL = 60 mg/kg/day / maternal toxicity, increase in pre- and post-implantation loss,

decreased foetal body weight

Species: Rat Male Fertility

Result: NOAEL = 40 mg/kg/day (maximum dose tested)

Species: Rat

Specific target organ toxicity -

single exposure

None known.

Specific target organ toxicity repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Adverse effects might occur in the following organ(s) following overexposure: liver.

**ELTROMBOPAG OLAMINE** 

Repeat dose non-clinical studies Organ: bone marrow; blood

Aspiration hazard

Not available.

Mixture versus substance

information

No information available.

Not available. Other information

# **SECTION 12: Ecological information**

No information is available about the potential of this product to produce adverse environmental 12.1. Toxicity

effects. The product contains a substance which may cause long-term adverse effects in the

environment.

IC50

Components **Species Test results** 

## ELTROMBOPAG OLAMINE (CAS 496775-62-3)

# Aquatic

Activated Sludge

Respiration

Acute

	NOEC	Residential sludge	> 32 mg/l, 3 hours
Algae	EC50	Duckweed (Lemna minor)	1.57 mg/l, 7 days, Static renewal test, OECD 221

**NOEC** Duckweed (Lemna minor) 0.59 mg/l, 7 days

Residential sludge

Crustacea EC50 Water flea (Daphnia magna) 1.5 mg/l, 48 hours, Static test, OECD

Water flea (Daphnia magna) **NOEC** 

0.54 mg/l, 48 hours, Static test

> 320 mg/l, 3 hours, OECD 209

Fish EC50 Rainbow trout (Juvenile Oncorhyncus

NOEC

3.3 mg/l, 96 hours, Static renewal test, **OECD 203** 

Rainbow trout (Juvenile Oncorhyncus

2.1 mg/l, 96 hours

mykiss)

# MAGNESIUM STEARATE (CAS 557-04-0)

#### Aquatic

Acute

EC50 Fish Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours

latipes)

Microtox EC50 Microtox 12.5 mg/l, 15 minutes

Polyvinylpyrrolidone (CAS 9003-39-8)

Acute

IC50 Activated sludge > 1000 mg/l, 3 hours, Static test

Material name: PROMACTA TABLETS 128838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013 Components **Species Test results** 

Aquatic

Acute

Crustacea EC50 Water flea (Daphnia magna) 84 mg/l, 48 hours, Static test

> NOEC Water flea (Daphnia magna) 32 mg/l, 48 hours, Static test

Titanium dioxide (CAS 13463-67-7)

Aquatic

Acute

Crustacea EC50 Water flea (Daphnia magna) > 1000 mg/l, 48 hours, Static test

#### 12.2. Persistence and

degradability

#### Persistence and degradability

**Photolysis** 

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

**ELTROMBOPAG OLAMINE** 18 %, 28 days Modified MITI (II) Test.

MAGNESIUM STEARATE 77 %, 28 days BOD

Polyvinylpyrrolidone 0 %, 28 days Modified MITI test, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

> **ELTROMBOPAG OLAMINE** 4.52 (Measured).

**Bioconcentration factor (BCF)** 

**ELTROMBOPAG OLAMINE** 14, OECD 305, Measured

Species: Rainbow trout (Adult Oncorhyncus mykiss)

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5 86 Estimated

Mobility in general

Distribution

Octanol/water distribution coefficient log DOW

**ELTROMBOPAG OLAMINE** 0.96, pH 9

4.52, pH 7 > 4.1, pH 5

12.5. Results of PBT

Not available.

and vPvB assessment

12.6. Other adverse effects Not available.

## **SECTION 13: Disposal considerations**

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

Disposal methods/information

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. This material and its container must be disposed of as hazardous waste. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international regulations.

**Special precautions** Dispose in accordance with all applicable regulations.

## **SECTION 14: Transport information**

#### **ADR**

14.1. UN number UN3077

Environmentally hazardous substances, solid, n.o.s. (ELTROMBOPAG OLAMINE, 14.2. UN proper shipping

FORMULATED PRODUCT) name

9 14.3. Transport hazard

class(es)

Subsidiary class(es) Ш 14.4. Packing group 14.5. Environmental hazards Yes

Not available. **Tunnel code** 

9 Labels required Additional information:

**Special Provisions** 8, 146, 335, A112, B54, IB8, IP3, N20, T1, TP33

**IATA** 

UN3077 14.1. UN number

Environmentally hazardous substance, solid, n.o.s. (ELTROMBOPAG OLAMINE, FORMULATED 14.2. UN proper shipping

PRODUCT) name

9

14.3. Transport hazard

class(es)

Subsidiary class(es) Ш 14.4. Packing group Labels required 9 **Additional Information:** 

Allowed Passenger & cargo **Packaging Instruction** 956 Pkg Inst cargo only 956 Pkg Inst pasenger & cargo Y956

LQ

SP See 44 A97,A158,A179

400 kg Max net qty pkg Max net gty pkg cargo only 400 kg Max net qty pkg LQ 30 kg G

**IMDG** 

14.1. UN number UN3077

ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (ELTROMBOPAG OLAMINE, 14.2. UN proper shipping

name

FORMULATED PRODUCT) 9

14.3. Transport hazard

class(es)

Subsidiary class(es) Ш 14.4. Packing group 14.5. Environmental hazards Marine pollutant Yes Labels required 9 F-A, S-F **EmS** 

14.6. Special precautions

for user 14.7. Transport in bulk

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

according to Annex II of environment. These materials may not be transported in bulk.

Not available.

MARPOL73/78 and the IBC Code

128838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013



Marine pollutant



## **SECTION 15: Regulatory information**

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA Not listed.

#### **Authorisations**

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended Not listed.

#### Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

## Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work Not listed.

SDS UK

## Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations 15.2. Chemical safety Follow national regulation for work with chemical agents. No Chemical Safety Assessment has been carried out.

assessment

## **SECTION 16: Other information**

**List of abbreviations** Not available.

**References** GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R22 Harmful if swallowed.

R36/37/38 Irritating to eyes, respiratory system and skin.

R41 Risk of serious damage to eyes. R51 Toxic to aquatic organisms.

R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R53 May cause long term adverse effects in the aquatic environment.

H302 Harmful if swallowed. H315 Causes skin irritation. H318 Causes serious eye damage. H319 Causes serious eye irritation. H335 May cause respiratory irritation.

H373 May cause damage to organs through prolonged or repeated exposure.

H411 Toxic to aquatic life with long lasting effects.
H412 Harmful to aquatic life with long lasting effects.
Product and Company Identification: Synonyms

**Revision information** Product and Company Identification: Synonyms Composition / Information on Ingredients: Ingredients

**Training information**Follow training instructions when handling this material. **Disclaimer**The information and recommendations in this safety data

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express

or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: PROMACTA TABLETS

12838 Version No.: 15 Revision date: 29-November-2013 Issue date: 29-November-2013 12 / 12

SDS UK